PUBLISHER: IMARC | PRODUCT CODE: 1540878
PUBLISHER: IMARC | PRODUCT CODE: 1540878
The global COVID-19 diagnostics market size reached US$ 63.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 30.6 Billion by 2032.
COVID-19 diagnostics refer to the clinical tests conducted to detect the presence of the viral infection among individuals. COVID-19 is an infectious disease caused by the newly discovered zoonotic coronavirus. Some common symptoms include fever, fatigue, dry cough, shortness of breath, sore throat and body aches. The viral infection is usually diagnosed through reverse transcriptase-polymerase chain reaction (RT- PCR), antigen-based and antibody testing. These tests use reagents and kits to obtain the sample from nasopharyngeal (NP), oropharyngeal (OP) and nasal swabs, human saliva or blood. They are widely used in hospitals, laboratories, clinics, research institutes and diagnostic centers.
The sudden outbreak of coronavirus disease and an alarming increase in the number of COVID-19 cases across the globe are among the key factors creating a positive outlook for the market growth. The continuous rise in the number of daily cases has led to the widespread adoption of diagnostic tests for rapid and comprehensive testing to provide early treatment to the patients. In line with this, the increasing demand for mass testing and molecular diagnostics is contributing to the market growth. Additionally, various product innovations, such as the launch of novel antibody and serology test kits for home-testing, are acting as other growth-inducing factors. In comparison to the traditionally used testing kits, these variants are less time-consuming and can be integrated with software-based programs for accurate results. Other factors, including the implementation of favorable government polices to prevent the further spread of COVID-19 infection, along with significant improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global COVID-19 diagnostics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product type, sample type, test type, mode and end use.
Reagents and Kits
Instruments
Others
Nasopharyngeal Swabs
Oropharyngeal Swabs
Nasal Swabs
Blood
Others
Molecular (RT-PCR) Testing
Antigen-based Testing
Antibody (Serology) Testing
Others
Point-of-Care (PoC)
Non-Point-of-Care (Non-PoC)
Laboratories
Hospitals
Diagnostic Centers and Clinics
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories, Danaher Corporation, F. Hoffman-La Roche Ltd. (Roche Holding AG), Luminex Corporation, PerkinElmer Inc., Quest Diagnostics Incorporated, Robert Bosch GmbH, Seegene Inc., Siemens Aktiengesellschaft and Thermo Fisher Scientific Inc.